Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Hikal
BSE:524735 Community
1
Narratives
written by author
0
Comments
on narratives written by author
1
Fair Values set
on narratives written by author
Create a narrative
Hikal
Popular
Undervalued
Overvalued
Hikal
WA
Analyst Price Target
Consensus Narrative from 2 Analysts
New Panoli Facility And Global Expansions Will Strengthen Operations Over Next 2-3 Years
Key Takeaways Strategic focus on operating leverage and product mix is set to improve net margins and revenue diversification. Advancements in CDMO projects and geographic expansions poise Hikal for significant revenue growth and market share increase.
View narrative
₹435.00
FV
18.4% undervalued
intrinsic discount
13.87%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Your Valuation for
524735
Hikal
Your Fair Value
₹
Current Price
₹355.05
2.2% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
34b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹34.2b
Earnings ₹1.4b
Advanced
Set as Fair Value